Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

17-Jan-2011 - Germany

Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec. The milestone reached was on the transition of an oncology programme into lead optimisation.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: "This is the eleventh milestone achieved as part of this alliance with Boehringer Ingelheim and the second against an oncology target.  We continue to enjoy a very rich scientific partnership with Boehringer Ingelheim and look forward to continued success through our joint project teams in the coming years".

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances